Skip to main content

Table 2 Druggability analysis results

From: Gene regulatory network inference: evaluation and application to ovarian cancer allows the prioritization of drug targets

Gene name Gene type Targeted drugs
Top 10 target genes   
   BCHE Enzyme Bicalutamide, genistein, choline, isoflurophate, hexafluorenium, demecarium bromide, echothiophate iodide, butyric acid
   CDK7 Protein kinase Lycopene, genistein, flavopiridol
   DKK1 Receptor ligand Decitabine
   CCR7 GPCR Decitabine
   TPI1 Enzyme Fluorouracil, quercetin
   HSD17B2 Enzyme NADH
   HBB Transporter Iron-dextran complex
Angiogenesis genes: SP3 targets   
   TIMP3 Binding protein Salinomycin, decitabine, sulindac, adaphostin
   CAV1 Binding protein Decitabine, progesterone, mifepristone
   CALB2 Binding protein Oxaliplatin, fluorouracil
   LAMB1 Receptor ligand Benzamidine, carebastine, anistreplase, tenecteplase
   DPYD Enzyme Oxaliplatin, gemcitabine, docetaxel, s1(combination), capecitabine, cisplatin, fluorouracil, tegafur, carboplatin, paclitaxel, genistein, enfuvirtide, raltitrexed, amifostine, irinotecan, methotrexate, mitoguazone, uracil
Angiogenesis genes: NFκB1 targets   
   KDR Receptor with enzyme activity Epigallocatechin gallate, resveratrol, sorafenib, sunitinib, bevacizumab, sirolimus, conivaptan, zonampanel, SU6668, vatalanib, vandetanib, axitinib, cediranib, trapoxin, motesanib, E-7080, erlotinib, Ca0456456, geldanamycin
   FGF13 Receptor ligand Bicalutamide
   PRRX1 Transcription factor Alitretinoin
   AOX1 Enzyme Isovanillin, norcantharidin, NSC336628
  1. Genes and anti-cancer drugs targeting their products were obtained using Cancer Resource and PharmGKB webtools and databases. GPCR, G-protein-coupled receptor.